Sleep Initiation and Maintenance Disorders
📧 Sign up to get email alerts when something new happens for Sleep Initiation and Maintenance Disorders.
Sign up freeTop drugs studied for this disease
-
EMA withdrawal · 2015-10-21EMA Withdrawn: Sonata (zaleplon) — Meda AB
The EMA has withdrawn Sonata (zaleplon) from the market in Europe (MAH: Meda AB) with a decision dated 03/07/2015.
-
EMA withdrawal · 2012-10-15EMA Withdrawn: Zerene (zaleplon) — Meda AB
EMA has withdrawn Zerene (zaleplon) from the market (Meda AB) for sleep initiation and maintenance disorders.
-
EMA withdrawal · 2010-06-01EMA Application withdrawn: Sliwens — Sanofi Aventis
The EMA withdrew the application for Sliwens by Sanofi Aventis in the sleep initiation and maintenance disorders therapeutic area.